Cargando…

LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis

Long noncoding RNAs (lncRNAs) are important regulators in cancer progression. Deregulation of the lncRNA taurine upregulated gene 1 (TUG1) predicts poor prognosis and is implicated in the development of several cancers. In this study, we investigated the role of TUG1 in the pathogenesis of intrahepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Bing, Ye, Huilin, Chen, Jianming, Cheng, Di, Cai, Canfeng, Chen, Guoxing, Chen, Xiang, Xin, Haiyang, Tang, Chaoming, Zeng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768353/
https://www.ncbi.nlm.nih.gov/pubmed/29371936
http://dx.doi.org/10.18632/oncotarget.21922
_version_ 1783292689236623360
author Zeng, Bing
Ye, Huilin
Chen, Jianming
Cheng, Di
Cai, Canfeng
Chen, Guoxing
Chen, Xiang
Xin, Haiyang
Tang, Chaoming
Zeng, Jun
author_facet Zeng, Bing
Ye, Huilin
Chen, Jianming
Cheng, Di
Cai, Canfeng
Chen, Guoxing
Chen, Xiang
Xin, Haiyang
Tang, Chaoming
Zeng, Jun
author_sort Zeng, Bing
collection PubMed
description Long noncoding RNAs (lncRNAs) are important regulators in cancer progression. Deregulation of the lncRNA taurine upregulated gene 1 (TUG1) predicts poor prognosis and is implicated in the development of several cancers. In this study, we investigated the role of TUG1 in the pathogenesis of intrahepatic cholangiocarcinoma (ICC). We found that TUG1 is upregulated in ICC samples, which correlates with poor prognosis and adverse clinical pathological characteristics. Knockdown of TUG1 inhibited the proliferation, motility, and invasiveness of cultured ICC cells, and decreased tumor burden in a xenograft mouse model. When we explored the mechanisms underlying these effects, we found that TUG1 acts as an endogenous competing RNA (ceRNA) that ‘sponges’ miR-145, thereby preventing the degradation of Sirt3 mRNA and increasing expression of Sirt3 and GDH proteins. Accordingly, glutamine consumption, α-KG production, and ATP levels were dramatically decreased by TUG1 knockdown in ICC cells, and this effect was reversed by miR-145 inhibition. These findings indicate that the TUG1/miR-145/Sirt3/GDH regulatory network may provide a novel therapeutic strategy for treatment of ICC.
format Online
Article
Text
id pubmed-5768353
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57683532018-01-25 LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis Zeng, Bing Ye, Huilin Chen, Jianming Cheng, Di Cai, Canfeng Chen, Guoxing Chen, Xiang Xin, Haiyang Tang, Chaoming Zeng, Jun Oncotarget Research Paper Long noncoding RNAs (lncRNAs) are important regulators in cancer progression. Deregulation of the lncRNA taurine upregulated gene 1 (TUG1) predicts poor prognosis and is implicated in the development of several cancers. In this study, we investigated the role of TUG1 in the pathogenesis of intrahepatic cholangiocarcinoma (ICC). We found that TUG1 is upregulated in ICC samples, which correlates with poor prognosis and adverse clinical pathological characteristics. Knockdown of TUG1 inhibited the proliferation, motility, and invasiveness of cultured ICC cells, and decreased tumor burden in a xenograft mouse model. When we explored the mechanisms underlying these effects, we found that TUG1 acts as an endogenous competing RNA (ceRNA) that ‘sponges’ miR-145, thereby preventing the degradation of Sirt3 mRNA and increasing expression of Sirt3 and GDH proteins. Accordingly, glutamine consumption, α-KG production, and ATP levels were dramatically decreased by TUG1 knockdown in ICC cells, and this effect was reversed by miR-145 inhibition. These findings indicate that the TUG1/miR-145/Sirt3/GDH regulatory network may provide a novel therapeutic strategy for treatment of ICC. Impact Journals LLC 2017-10-19 /pmc/articles/PMC5768353/ /pubmed/29371936 http://dx.doi.org/10.18632/oncotarget.21922 Text en Copyright: © 2017 Zeng et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zeng, Bing
Ye, Huilin
Chen, Jianming
Cheng, Di
Cai, Canfeng
Chen, Guoxing
Chen, Xiang
Xin, Haiyang
Tang, Chaoming
Zeng, Jun
LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title_full LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title_fullStr LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title_full_unstemmed LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title_short LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
title_sort lncrna tug1 sponges mir-145 to promote cancer progression and regulate glutamine metabolism via sirt3/gdh axis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768353/
https://www.ncbi.nlm.nih.gov/pubmed/29371936
http://dx.doi.org/10.18632/oncotarget.21922
work_keys_str_mv AT zengbing lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT yehuilin lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT chenjianming lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT chengdi lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT caicanfeng lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT chenguoxing lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT chenxiang lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT xinhaiyang lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT tangchaoming lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis
AT zengjun lncrnatug1spongesmir145topromotecancerprogressionandregulateglutaminemetabolismviasirt3gdhaxis